Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKOSOL vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, chronic bronchitis, emphysema)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via catechol-O-methyltransferase (COMT); also undergoes sulfate conjugation.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40–60% bound to albumin, with some binding to alpha-1-acid glycoprotein.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Approximately 0.5 L/kg, indicating distribution into total body water and moderate tissue binding.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Inhalation: 10–20% (variable due to deposition and first-pass metabolism); oral: <1% due to extensive first-pass metabolism.
Oral: 40-50%; Inhalation: 20-30%
No dose adjustment required for renal impairment.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No specific guidelines; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
0.01-0.03 m L/kg of 0.5% solution (maximum 0.5 m L) via nebulization every 4-6 hours as needed.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initiate at lowest effective dose; monitor for tachycardia and hypertension.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None
No FDA black box warning.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: tachycardia, hypertension, arrhythmias,Hypokalemia may occur with high doses,Caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to isoetharine or any component,Cardiac arrhythmias associated with tachycardia,Tachycardia or heart block caused by digitalis intoxication
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No significant food interactions. Avoid excessive caffeine intake as it may increase beta-agonist side effects (tremor, tachycardia). No specific dietary restrictions.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bronchodilator use; systemic exposure minimal. However, uncontrolled asthma poses greater risk (maternal hypoxia, preterm birth).
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excreted in breast milk in small amounts. M/P ratio not reported. Inhaled route minimizes systemic absorption; unlikely to affect nursing infant. Use with caution, weigh risks vs benefits.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No dose adjustment typically required. Pregnancy may alter asthma severity; titrate dose to achieve symptom control. Inhaled beta-2 agonists generally safe; no significant pharmacokinetic changes reported.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Bronkosol (isoetharine) is a beta-2 selective bronchodilator, but with less beta-2 selectivity than albuterol; monitor for tachycardia and tremor. It is administered via nebulization; ensure proper equipment and technique. Onset within 2-5 minutes, duration 1-3 hours. Not a first-line agent; use primarily for acute bronchospasm when albuterol is unavailable. Paradoxical bronchospasm can occur; discontinue if worsens.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you miss a dose, use it as soon as you remember, but skip if it's almost time for the next dose; do not double up.,Rinse your mouth with water after each use to prevent dryness and irritation.,Seek immediate medical help if symptoms worsen or you experience chest pain, fast heartbeat, or difficulty breathing after use.,Store at room temperature away from moisture and heat; keep nebulizer clean per instructions.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKOSOL vs AEROLATE III, answered by our medical review team.
BRONKOSOL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKOSOL and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKOSOL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKOSOL and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKOSOL is classified as Category C. FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bron. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.